Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post by Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, on X:
“With this practice-changing study we learned that ‘some pembro’ is better than ‘no pembro’ in patients scheduled for preop chemo.
Yet, by my no means does it confirm that ‘more pembro’ after surgery further helps already-responders (MPR and pCR) or non-responders.”
Quoting Jonathan Spicer’s post:
“KN671 OS and HRQoL!
Check it out.”
Authors: Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Prof Se-Hoon Lee, Prof Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Prof Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie E Chaft, Prof Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M Keller, Ayman Samkari, Shugeng Gao
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023